beovu survey indic best time worst time
rais eylea revenu estim price target base two separ retin
specialist survey one field one asr beovu safeti
commun bottom line overst impact concern
see market upend essenti overnight specif asr
commun aproprietari survey retin specialist project beovu
grab wet-amd patient august eylea share bp sinc
safeti updat went back doc mani express mistrust
nv cut beovu project half actual project eylea share growth
rais eylea estmat buyer level approach
time everyth beovu safeti concern came light survey
high volum retin specialist collect manag wet-amd dme
patient feedback great last week went back
doc feedback could differ highlight herein
vegf market appear midst upheav scale rare seen
could ugli eylea long felt beovu oversold
aggress novarti nv market effort doc buy percept
beovu offer better efficaci extend dose doc project patient
share august mostli expens eylea impli revenu downsid
lightn struck world chang asr commun regard
case occlus vascul beovu treat patient true event
beovu label experi doc rare read packag insert often
reli better wors sales/msl messag given survey
doc feedback starkli differ specif beovu share
project august half pre-asr commun moreov mani
doc voic anger mistrust nv indic uphil battl nv
rais eylea number price target eylea share project
grow slightli august given decidedli neg beovu sentiment
adjust us eylea number upward
respect yield new price target may
see regn recent strength indic upsid price stock think
magnitud shift percept project use may yet surpris call
et tomorrow review result detail pleas contact piper sandler
rep dial-in inform
commerci regulatori clinic ip risk associ market pipelin product
regeneron develop market therapi address varieti diseas
back
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
best time
worst time
page
page
page
survey
question on-line survey high-volum ophthalmologist execut partnership guidepoint
subsequ asr commun beovu associ occlus vascul field follow-up survey
cohort ophthalmologist follow-up yield respons ophthalmologist field februari
least ivt-treat wet patient person manag
survey relat graphic herein guidepoint piper sandler
page
first survey ophthalmologist early-februari went back last week asr commun
safeti concern beovu relat occlus retin vascul
beovu
pretti
early-februari doc prescrib beovu captur wet market share beovu
patient either ivt tx-nave switch eylea less-frequ dose
novarti aggress market beovu high sale rep contact rate survey doc seen
beovu rep within previou month vs eylea time beovu rep counter-detail eylea
ophthalmologist report good satisfact beovu particularli dose frequenc agre
repres signific advanc ivt wet
safeti
game-
doc survey feb awar asrss feb commun regard beovu
associ occlus retin vascul
doc less like initi tx-nave tx-experienc patient beovu respect
doc say switch exist beovu patient differ anti-vegf therapi
beovu wet market share project fell dme project share fell
doc say beovu new safeti concern make like prescrib eylea
doc previous project eylea wet share fall within month doc project
increas eylea wet share
rais us eylea revenu estim respect
page
page
practic averag year
manag averag wet patient
patient dme patient captur
half patient cover medicar
question long practic follow best describ practic set mani patient follow eye disord current treat
pleas provid estim health insur mix patient pleas note answer must sum
page
amddmepati mixva/dod/tricareself-paymedicaidcommercial//thirdparty/hmomedicar current treatment trend
page
ivt treatment rate current market share
wet patient dme
patient treat intravitr ivt
eylea avastin captur wet
market share beovu
dme eylea market share ahead
avastin beovu share
question previous state current treat approxim wet patient dme patient intravitr pharmacotherapi percent
intravitreal-pharmacotherapeutically-tr patient wet dme current treat follow product
page
-ivt market share -ivt market share dmeivt treatment ratesmeanmedian beovu trend
doc alreadi prescrib
two-third survey
ophthalmologist prescrib beovu
much fewer doc report
prescrib beovu dme
beovu patient sourc concern
close half beovu patient either ivt
nave switch eylea less-
would concern eylea
subsequ asr commun
discuss herein
previous assum much
larger share beovu patient would
switch eylea efficaci failur
account beovu
question percent intravitreal-pharmacotherapeutically-tr patient wet dme current treat follow product
think prior ivt therapi patient current treat beovu percentag
page
use -wet patient sourceswitch lucentisswitch avastinswitch eyleaaft efficaci failureswitch eylea forless frequent dosingivt use -dmeusernon-us
eylea patient dose less
frequent
dose
dose frequent
beovu patient dose less
frequent doc also report
high proport beovu
patient treat
assum relat load dose
though question specif ask
dose frequenc mainten
wet eylea dme
patient dose less frequent
dose
dose frequent
dose prn
doc report beovu use
dme would read much
dose frequenc trend
question consid wet patient mainten ivt therapi dose follow frequenc consid dme patient mainten
ivt therapi dose follow frequenc note number may sum due round
page
frequenc -wet frequenc challeng wet amd/dm
ask respond select main challeng treatment wet dme
unsurprisingli inject frequenc top choic indic follow manag care access
question main challeng treatment follow diseas pleas select appli
page
frequencymanag care accesslogist timeconstraint clinicpersonnelsafeti includinginflamm etc challeng wet amd/dmewet amddm brand select respons measur
doc care visual acuiti
ask import factor
choos therapi wet amd/dm patient
improv anatom outcom distant
second select ophthalmologist
retin thick use measur respons
ophthalmologist use oct measur
respons wet patient
dme patient treat ivt
relev eylea
recal beovu program
improv anatom outcom compar
eylea nv indic doc top
concern anatom outcom
eylea show numer advantag bcva
week hawk harrier
doc indic bcva drive brand select
rather anatom outcom
question import choos therapi wet dme patient measur respons patient treat intravitr
pharmacotherapi wet dme pleas select appli
page
respons measurementwet acuity/vis visualacu bcva improv anatomicoutcom cst/fluidrecurr safetyaccessdos frequencyotherdriv ivt brand select overal satisfact highest eylea
scale satisfi
extrem satisfi doc rate overal
satisfact eylea ahead lucenti
avastin
doc provid satisfact rate
beovu give
overal satisfact score lower across
board dme eylea still
favor therapi averag ahead
lucenti avastin
doc provid overal satisfact
score beovu dme give
detail attribut rate next page
note respond rank
satisfact eylea dose frequenc either
compar beovu
question pleas rate overal satisfact follow intravitr pharmacotherapi treatment option treatment wet dme use scale satisfi
extrem satisfi note exclud respons ophthalmologist unfamiliar beovu wet ophthalmologist unfamiliar beovu
page
satisfact -wet extrem satisfiednot familiar/not satisfact extrem satisfiednot familiar/not applic satisfact current option detail
question pleas rate follow product list attribut scale perform extrem poorli perform extrem lucenti eylea beovu
page
frequencyaccessoopeylea frequencyaccessoopbeovu extrem satisfiednot familiar/not extrem satisfi wet dme discontinu
avastin highest discontinu rate year treatment discontinu
driven lack efficaci
eylea patient discontinu year driven cost lack efficaci
far beovu user report discontinu rate half driven cost driven tolerability/safeti
question patient wet dme start follow product percentag discontinu agent within first year reason could
includ discontinu therapi switch product etc product pleas indic reason discontinu avastin lucenti
eylea beovu note number may sum due round
page
discontinuationsupplytolerability/safetypati choicedesir less frequent dosingsteadi state visual acuiti reacheddiseas progression/non-respondercost statement agreement
compound avastin suppli shortag appear dissip respond report suppli
disrupt past month past month
addit dose eylea label minim impact prescrib trend avail
eylea pre-filled syring like tailwind doc agre increas eylea prescrib
doc say addit dose
eylea label impact prescrib trend
doc say pre-filled syring
increas eylea prescrib volum
question pleas rate level agreement follow statement regard treatment trend wet dme use scale strongli disagre
strongli agre note number may sum due round
page
avail eylea pre-filled syring increas eylea prescribingvolumeth addit dose eylea label august caus increas dose interv eylea patientsmi practic experienc suppli disrupt repackag avastin thepast monthsmi practic experienc suppli disrupt repackag avastin thepast monthsblankn/a strongli strongli agre beovu percept shift measur
page
beovu safeti concern came late-februari
februari macula societi meet data regard
beovu post-market present includ case
retin occlus vascul retin specialist social media
describ worri data
februari asr american societi retina specialist sent
email commun member disclos case
vascul beovu-tr patient
design occlus retin vascul report
februari novarti issu statement acknowledg
asr commun indic compani engag
extern safeti review committe evalu beovu
safeti fda health author awar
februari field follow-up survey got
respons ophthalmologist particip
origin survey respond awar asr
march novarti issu press releas indic stand behind safeti efficaci beovu use
indic comprehens review limit number report case sever vision loss inflamm
potenti retin vascul patient treat beovu underway though believ incid event
remain consist packag insert releas specifi classif report
yet establish case present first second inject beovu patient report chang
vision within week treatment
asr novarti piper sandler note emphasi ad psc
question awar februari commun asr american societi retin specialist regard report occlus retin vascul link beovu use
page
asr commun yesno beovu safeti
sens fda may downplay safeti concern beovu particularli compar eu regul
exampl us beovu label simpli list activ intraocular inflamm contraind show beovu higher
rate ioi retin arteri occlus trial contrast eu prescrib inform list ioi contraind
also explicitli call risk retin arteri occlus
eu review document elucid potenti mechan occlus retin vascul see highlight section
excerpt beovu us label
excerpt beovu eu label
excerpt beovu eu review document
page
survey earli februari asr safeti commun beovu ophthalmologist gener
favor opinion beovu efficaci agre repres signific advanc wet
therapi agre superior efficaci eylea
howev half doc indic beovu high rate inflamm would barrier use
half indic beovu lack monthli dose option label lack approv indic outsid wet
would neg impact willing stock/prescrib beovu fewer doc said lack pre-filled
beovu statement agreement earli februari
puzzlingli doc agre beovu superior
improv eylea bcva
doc agre beovu ioi barrier use
beovu lack approv outsid wet barrier doc
doc dont view beovu lack pre-filled syring barrier
question pleas rate level agreement follow statement regard treatment trend wet dme use scale strongli disagre strongli
agre note number may sum due round
page
lack pre-filled syring option neg impact willing stock/prescrib beovuth lack approv indic outsid wet neg impact mywilling stock/prescrib beovuth lack monthli dose option beovu label neg impact willing stock/prescrib beovubeovu higher rate intraocular inflamm clinic trial vs eylea repres signific barrier use beovubeovu clinic efficaci statist noninferior numer inferior bcva improv vs eylea hawk harrier superior eyleabeovu repres signific advanc avail intravitreallyadminist pharmacotherapi wet n/a strongli strongli agre beovu percept shift drastic post-asr commun
follow respond asr commun beovu link occlus vascul
say beovu higher rate inflamm barrier use vs earli februari
almost respond say beovu associ occlus retin vascul make less like initi tx-nave patient beovu
less like switch patient beovu addit doc say switch current beovu patient differ anti-vegf therapi
doc larg view occlus vascul beovu-specif problem agre beovu rate differ anti-vegf
doc say beovu bcva advantag
eylea vs pre-asr commun
ioi
barrier use
doc view occlus retin vascul beovu-specif problem anoth unsur
question pleas rate level agreement follow
statement regard treatment trend wet dme use scale
strongli disagre strongli agre
note number may sum due round
page
believ beovu rate occlus retin vascul turn differ anti-vegf therapiesbecaus asr commun regard beovu associ occlus retin vascul willswitch exist beovu patient differ anti-vegf therapi beovu associ occlus retin vascul make less like switch patient beovu beovu associ occlus retin vascul make less like initi treatment-navepati beovu beovu higher rate intraocular inflamm clinic trial vs eylea repres signific barrier use beovu beovu clinic efficaci statist noninferior numer inferior bcva improv vs eylea hawk harrier superior eylean/a strongli strongli agre eylea stand benefit beovu safeti concern
ask doc beovu safeti concern impact prescrib pattern anti-vegf agent
unsurprisingli say less like prescrib beovu
say like prescrib eylea compar like prescrib lucenti
avastin respect
doc much less like prescrib beovu post-asr commun
chang likelihood prescrib ivt agent post-asr commun
doc like prescrib eylea result beovu safeti concern
question impact asr commun beovu risk occlus retin vascul prescrib behavior follow agent pleas use scale
much less like prescrib impact likelihood prescrib much like prescrib note number may sum due round
page
much less like impact likelihood much like prescrib asr open-end respons
ask doc comment safeti concern earli experi use beovu group respons five categori
ye everybodi stop use
compani
respons disclos catastroph
seen sever case vitriti one
case occlus vascul safeti issu
sever seen ivt
anti-vegf drug experi find
revel novarti saw retin arteri
occlus pivot studi classifi
gener inflamm disingenu
inspir trust compani
handl current issu market
concern previous rate
steril inflamm im concern
hold new prescript
clariti issu
need figur peopl
confid give beovu would like know
peopl develop vascul got
first inject subsequ inject
ration use beovu
investig occlus vascul
question comment earli experi beovu safeti concern beovu
note emphasi ad psc
page
concern
new horv report concern
signific concern safeti point
concern occlus retin report
occlus retin vascul associ beovu particularli concern
concern occlus diseas common inflamm
comment concern side effect medicin
beovu superior eylea term dri effect concern rel high rate occlus vascul
seriou uveiti
seem dri better concern difficult treat patient abl get month interv
inflamm anoth hurdl
earli tell point
want watch futur asr updat
promis reserv final judgement
use sure fit time
might show result med
earli say real problem
wait make chang
problem patient far
efficaci mild inflamm respons topic drop
none realli far issu
yet issu preliminari data need
review
question comment earli experi beovu safeti concern beovu
note emphasi ad psc
page
page
first field survey earli februari doc project eylea share wet would declin
next six month see pre-asr data time doc project beovu
would gain share increas
howev safeti concern beovu becom known doc project beovu share half
initi project eylea share remain essenti flat next six month label post-asr
current project share
full initi particip
asr commun doc
thought eylea would drop wet
post-asr commun
project eylea share increas
asr
would grow
commun
project beovu share
increas
note respond
initi survey particip follow-
survey current project wet
share pre-asr respond
shown
question think overal ivt-treat wet patient load percent patient are/do anticip therapi current next month
current pre-asr post-asr graph tabl right note data doc respond initi survey follow-up survey post-asr
shown graph show data doc survey initi survey tabl right page
page
ivt share -current month pre-and post-asr commun month pre-asr month post-asr current project use dme
doc initi project beovu market share dme would increas within six month see pre-
asr data expect modest eylea eros
howev asr novarti commun new safeti concern beovu doc project minim beovu
market share growth dme next six month doc survey asrss februari
commun still expect eylea share somewhat lower six month
current project share
full initi particip
asr commun
would declin post-asr
project eylea
note respond
initi survey particip follow-
survey current project dme
share pre-asr respond
shown
asr
would increas
dme post-asr
project fallen
question think overal ivt-treat dme patient load percent patient are/do anticip therapi current next month
current pre-asr post-asr graph tabl right note data doc respond initi survey follow-up survey post-asr
shown graph show data doc survey initi survey tabl right page
page
ivt share -current month pre-and post-asr commun month pre-asr month post-asr current project beovu initi
initi field survey earli februari
doc project beovu initi variou
timepoint come year fairli robust
shown blue label pre-asr chart
howev went back physician
patient initi cut half
true near-term next month initi
expect fell long-term
month initi expect fell
trend dme beovu patient initi
question approxim mani beovu patient initi expect make
within next month
prior survey ask expect beovu patient initi prior
respons shown tabl interest whether asr commun
beovu chang expect beovu initi approxim mani
beovu patient initi expect make within next month
page
page
novarti aggress market beovu doc report sale rep contact within past month vs
question therapi last time contact compani repres sale rep msl etc
note number may sum due round
page
ask doc describ main messag commun rep group respons categori shown
chart note actual respons shown appendix
survey field earli februari beovu eylea rep emphas dose frequenc access/practic
support would think messag beovu eylea rep shift beovu safeti profil
question main messag commun compani repres sale rep msl etc lucenti eylea beovu
page
frequencyaccess/practicesupportdirect comparisonto ivtind outsideof amdlong-term trackrecordotherdon rememberunaid messag recalllucentiseyleabeovu beovu rep eylea rep aggress counterdetail
beovu rep aggress counterdetail eylea report doc contrast doc say eylea rep
posit eylea beovu
think trend like shift follow disclosur beovu safeti issu
question recent discuss lucenti repres posit lucenti anoth ivt product pleas select appli recent
discuss eylea repres posit eylea anoth ivt product pleas select appli recent discuss beovu repres
posit beovu anoth ivt product pleas select appli
page
repeylea repbeovu repcounterdetail recent rep contactlucentiseyleabeovunot posit anoth ivtother/don rememb pipelin
page
ophthalmologist say less frequent dose better improv visual acuiti area greatest unmet need
question would like know consid greatest unmet need new agent treat wet pleas rate level unmet need follow attribut scale
unmet need signific unmet need
page
frequent dosingimprov visual acuiti bcva conveni deliveryimprov anatomicoutcom cst/fluidrecurr lack need loadingdosesimprov safetyunmet need wet signific unmet unmet need familiar
familiar highest roch lucenti port faricimab follow allergan abicipar pegol
gene therapi adverum regenx long-act agent rel lower familiar rate
question pleas rate familiar follow development candid familiar extrem familiar
page
port genentech faricimab genentech abicipar pegol aflibercept genetherapi anti-vegf genetherapi graybug vision familiar agent develop wet extrem port genentech faricimab genentech abicipar pegol aflibercept genetherapi anti-vegf genetherapi graybug vision familiar agent develop wet extrem familiar ideal dose frequenc
ask doc prefer dose frequenc new wet amd/dm agent frequently-chosen respons
indic doc would like see treat patient per year
interestingli doc look someth dose year
next page includ doc rational choos ideal dose frequenc
question new wet amd/dm agent assum equival efficacy/safety/access current approv agent would ideal dose frequenc
page
dose frequenc year year select pipe dose frequenc
amount time visit ensur patient improv
less burden still follow patient
long enough burden short enough abl continu monitor
consist greater dose similar efficaci would step
reason time frame patient follow
would still abl monitor esp dme patient burdensom
treatment patient
twice year three time year dose patient like rememb need
care long patient get lost follow diseas may continu
unfett time caus irrevers loss
mean would see patient
would want see back clinic evalu
although longer treatment interv may seem attract examin
potenti treat patient blind condit twice year seem
infrequ inject allow period monitor possibl failur
avoid patient overconfid requir monitor
long short plu frequent dose
revenu oppti practic
less frequent inject low side effect
twice yearli reason want keep monitor patient
would minim time visit diseas could
treat visit
twice yearli reason want keep monitor patient
would minim time visit diseas could
treat visit
less risk patient
like least injections/treat possibl
obvious fewer treatment would better patient
least frequent interv list
less frequenc equal efficaci better
would nice patient good better vision long-term basi
inject year reason patient still need monitor
without need frequent inject risk infect
everi month ideal balanc efficaci need continu follow
longest
best patient
ideal dose interv reduc treatment burden enabl watch
patient care
would want see patient clinic everi month anyhow want
back offic also payor resist anyth whose durat
last longer patient insur product want
pay drug benefit anoth payor if/when patient chang insur plan
year complic incomplet respons want
deal indefinit month long care go
need regular follow-up monitor balanc minim inject frequenc
minim potenti advers effect sustain anti-vegf suppress
question select dose frequenc open answer
page
page
revamp us
eylea market model
data survey
assum eylea
maintain wet share
rang
beovu launch
assum modest increas
eylea share dme
market anti-vegf
page
age-rel macular degener us wet diagnos address wet treat ivt patient eylea eylea averag per wet revenu diabet macular edema us dme diagnos address ivt address dme eylea eylea averag per dme revenu diabet retinopathi without dmeu dr revenu crvo usu brvo/crvo revenu eylea psc model better reflect us eylea indic split
old vs new psc us eylea revenu estim indic
recal call manag gave
visibl us eylea revenu indic show
new estim better reflect
chart show new us eylea revenu broken
indic previou model proport us eylea
sale contribut dme high
underestim proport revenu come wet
eylea busi wet
busi migrat
greater sourc busi come diabet eye
diseas look overal
busi would also add probabl
math leav mayb busi come
diabet eye diseas approxim
busi come retin vein occlus
page
eylea estim indic us eylea revenu wet amdprior psc psc diseas dme dr prior psc psc psc psc commentari earn call psc vs consensu
increas us eylea sale
estim bring total revenu
ep estim well ahead consensu
provid extrem limit
visibl chang account
sanofi collabor result
restructur announc make
ep impact model chang
somewhat uncertain point expect
provid clariti later quarter
stay consist valuat
back
increas ep estim partial laps
discount period bring price target
prior
page
consensu total revenu increas
sinc asr commun
us eylea consensu increas sinc
consensu increas report
comparison may reflect low-qual consensu
us eylea line item think fair argument
consensu hasnt fulli bake impact eylea caus
new beovu safeti concern
page
page
question therapi main messag commun compani repres sale rep msl etc lucenti eylea beovu
page
main messag repslucentiseyleabeovuexemplari dose frequenc new data show extend week pretti often long durat effectcan use npdr without edema extend interv new long act efficaci frequenc superior efficaci durabilitygreat efficaci appli label potenti less frequent injectionsdurabilitysimilar outcom fewer injectionsapprov longer dosinglong treatment interv good efficaci tri hammer home point week dose especi beovu come fda approv pfsprefil syringetrack record long use safeti pre-filled syringeprefil syringeprefil syringepre-fil syringepre-fil syringeprefil syring avail pre-filled syring avail pre-fil syringepr fill strategi patient access assist program pre-filled syringeequ efficaci beovusuperior eyleabeovu resultscan extend longer eyleasafeti rebatessampl avail free sampl come want help make sure patient adequ access success therapeut option want make sure patient adequ access success therapeut option issu regard target-price approv academ hospit practic versu privat practic samplesassist program efficaci reimbus assistanceefficaci reimbus assistanceefficaci reimbus assistanceperman j-codesuppli samplesget readi get formulari institutionask need anyth sampl access solutionsefficaci reimbursementcontinu support practicej code avail wet amd onlypati assist programsavail help code order set portal use medicar patient co-pay cardthat insur compani readili cover medic good coverag initi usecan use multipl indic effect dme patient poor vaindic efficaci dose safetywork well mani indic approv monthli intervalto use dr without dme use lucenti drsafeti concernspleas consid beovupleas use eyleahawk harrier datadiffer mechan actionmi experi drugefficaci safetyresult excit doctor commun avail uselong term experi old proven still safe use product efficaci safetymost studi prove efficacystandard careno new messagecan rememb long ago long recal none yr dont rememb long otherlong-term track recorddon rememberdos frequencyprefil syringeaccess/practic supportdirect comparison ivtind outsid piper sandler co
good sold
product sale
collabor manufactur
collabor revenu
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
